![icad results canada icad results canada](http://www.icad-cisd.com/wp-content/uploads/CanadaPavilion_Report-AIDS2016.jpg)
Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets.
#Icad results canada software
In 2018, ProFound AI for DBT became the first artificial intelligence (AI) software for DBT to be FDA-cleared it was also CE marked and Health Canada licensed that same year. ProFound AI™ is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. Furthermore, the information presented herein does not present all information necessary for an understanding of the Company’s first quarter of 2021. iCAD’s final consolidated financial results as of and for the three months ended Mamay materially differ from estimates and the interim balances set forth in this release. The preliminary estimated financial information included in this press release for the three months ended Mais based solely on management’s estimates reflecting currently available preliminary information, and remains subject to iCAD’s consideration of subsequent events, particularly as it relates to material estimates and assumptions used in preparing our consolidated financial statements for the three months ended March 31, 2021. ICAD’s consolidated financial statements for the three months ended Maare not yet available. "I am proud to have worked with such a talented team with a track record of delivering on strategic and financial objectives.” “It has been exciting to be a part of the successful growth of iCAD and the expansion of our products and markets," said Mr. “Both our current VP of Finance and Controller will assume expanded responsibilities during this period of transition.” We wish Scott well in his future endeavors,” Mr. During his tenure as CFO, Scott played an instrumental role in helping accelerate revenue growth and strengthening our competitive position. “Scott has been a valued member of the iCAD team for 10 years, having served as CFO for the last two years. The search and selection process for a successor to Mr. An interim CFO will be appointed shortly to serve until such time as a permanent successor to Mr. Scott Areglado, will be leaving the Company in early May to accept a position with another company.
![icad results canada icad results canada](https://static1.seekingalpha.com/uploads/sa_presentations/644/58644/slides/39.jpg)
ICAD also today announced that its Chief Financial Officer (CFO), R. “Our strong results were driven by growth in both AI Detection revenue, due to continued market penetration for ProFound AI ® and ProFound AI ® Risk, and Xoft ® Therapy revenues.” “For the first quarter of 2021, anticipated final revenue numbers represent significant growth, compared to the first quarter of 2020,” according to Michael Klein, iCAD’s Chairman and CEO. Unaudited cash and cash equivalents as of Mawere approximately $46.9 million, which includes proceeds of the public offering closed in March 2021 that generated gross proceeds of approximately $25.0 million. Based on preliminary, unaudited financial information, the Company expects total revenue for the first quarter of 2021 to exceed $8.1 million. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the first quarter of 2021. NASHUA, N.H., Ap(GLOBE NEWSWIRE) - iCAD, Inc. Focused on being a good steward of land, livestock and people to create sustainable efforts for now and generations to come.Company expects preliminary estimated revenues to exceed $8.1 million Our client is a large Diversified Dairy Operation, multi-generational family owned and operating with high standards for animal health and welfare.